Omeros
About Omeros PipelineInvestorsNews

Management

The members of Omeros' management team contribute diverse expertise across all aspects of our scientific and corporate strategies. They provide Omeros with proven leadership to navigate the complex terrain of biopharmaceutical development and commercialization.

  • Gregory A. Demopulos, M.D.
    Gregory A. Demopulos, M.D.
    Chairman and Chief Executive Officer

    Gregory A. Demopulos, M.D. founded our company and has served as our president, chief executive officer and chairman of the board of directors since June 1994. Prior to founding Omeros, Dr. Demopulos completed his residency in orthopedic surgery at Stanford University and his fellowship

    Chairman and Chief Executive Officer
  • Christopher S. Bral, Ph.D.
    Christopher S. Bral, Ph.D.
    Vice President, Nonclinical Development

    Christopher S. Bral, Ph.D. joined Omeros as our vice president, nonclinical development in October 2015. From April 2014 to October 2015, Dr. Bral was the executive director, toxicology at Arrowhead Research Corporation. From June 2008 to April 2014, Dr. Bral served as director, drug sa

    Vice President, Nonclinical Development
  • Timothy M. Duffy
    Timothy M. Duffy
    Vice President, Business Development

    Timothy M. Duffy has served as our vice president, business development since March 2010. From November 2008 to March 2010, Mr. Duffy served as the managing director of Pacific Crest Ventures, a life science consulting firm that he founded. From June 2004 through September 2008, Mr. Duf

    Vice President, Business Development
  • Timi Edeki M.D., Ph.D.
    Timi Edeki M.D., Ph.D.
    Vice President, Clinical Development

    Timi Edeki, M.D., Ph.D. joined Omeros as our vice president, clinical in May 2017. Dr. Edeki is a pharmaceutical physician-scientist with experience in developing drugs in multiple therapeutic areas including nephrology, hematology, cardio-metabolic, immunology, antimicrobials, neurosci

    Vice President, Clinical Development
  • George A. Gaitanaris, M.D., Ph.D.
    George A. Gaitanaris, M.D., Ph.D.
    Chief Scientific Officer

    George A. Gaitanaris, M.D., Ph.D. joined Omeros as our vice president, science in August 2006 and has served as our chief scientific officer since January 2012. From August 2003 to our acquisition of nura, inc. in August 2006, Dr. Gaitanaris served as the chief scientific officer of nur

    Chief Scientific Officer
  • Michael A. Jacobsen
    Michael A. Jacobsen
    Chief Accounting Officer

    Mr. Jacobsen joined Omeros in August 2013 as our vice president, finance and has served as our chief accounting officer and treasurer since October 2013. Prior to joining Omeros, Mr. Jacobsen served as vice president of finance of Sarepta Therapeutics, Inc. from September 2011 to May 20

    Chief Accounting Officer
  • Marcia S. Kelbon, J.D., M.S.
    Marcia S. Kelbon, J.D., M.S.
    General Counsel and Secretary

    Marcia S. Kelbon, J.D., M.S. joined Omeros as our vice president, patent and general counsel in October 2001 and has served as our secretary since September 2007. Prior to joining Omeros, Ms. Kelbon was a partner with the firm Christensen O'Connor Johnson & Kindness, PLLC, where she

    General Counsel and Secretary
  • Daniel G. Kirby
    Daniel G. Kirby
    Vice President, Head of Commercial

    Daniel (“Dan”) Kirby joined Omeros in November 2018 as our Vice President, Head of Commercial. Prior to Omeros, Mr. Kirby was the U.S. CAR T-cell commercial lead for Celgene, joining Celgene as part of the Juno Therapeutics acquisition. At Juno, Mr. Kirby built and led commercial func

    Vice President, Head of Commercial
  • Eckhard S.D. Leifke, M.D.
    Eckhard S.D. Leifke, M.D.
    Chief Medical Officer

    Dr. Leifke joined Omeros as our Vice President, Clinical Development in June 2018 and assumed the role as our Chief Medical Officer in August 2018. He brings to Omeros more than 20 years of drug development experience, having built and headed global teams at leading pharmaceutical compa

    Chief Medical Officer
  • Justin McCue, Ph.D.
    Justin McCue, Ph.D.
    Vice President, Chemistry, Manufacturing and Controls

    Justin McCue, Ph.D. joined Omeros as our Vice President of Chemistry, Manufacturing and Controls (CMC) in September, 2018. Prior to joining Omeros, Dr. McCue headed the development of CAR T-cell and T-cell receptor (TCR) therapy manufacturing processes at Juno Therapeutics (now Celgene)

    Vice President, Chemistry, Manufacturing and Controls
  • Catherine A. Melfi, Ph.D.
    Catherine A. Melfi, Ph.D.
    Chief Regulatory Officer

    Catherine A. Melfi, Ph.D. joined Omeros as our vice president, regulatory affairs and quality systems in October 2012 and has served as our chief regulatory officer since April 2016. Dr. Melfi previously served from 1996 to 2012 at Eli Lilly and Company, where she held technical and lea

    Chief Regulatory Officer
  • J. Steven Whitaker M.D., J.D.
    J. Steven Whitaker M.D., J.D.
    Vice President, Clinical Development

    J. Steven Whitaker, M.D., J.D. has served as our vice president, clinical development since joining Omeros in March 2010, and served as our chief medical officer from March 2010 through August 2018. From May 2008 to March 2010, Dr. Whitaker served as the chief medical officer, vice pres

    Vice President, Clinical Development